A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome
- 73 Downloads
Objective: To evaluate the clinical effect and safety of Safflower Yellow injection (SYI) in treating coronary heart disease angina pectoris (CHD-AP) with Xin-blood stagnation syndrome (XBSS).Methods: Adopted was the multi-centered, randomized, positive parallel controlled method, 448 patients with CHD-AP-XBSS were enrolled and divided into two groups, 336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days, so as to observe the conditions of angina, electrocardiogram, and therapeutic effect on traditinal Chinese medicine (TCM) symptoms as well as the safety of the treatment.Results: The significantly effective rate and total effective rate in the tested group were 60.06% (194/323) and 91.02% (294/323) respectively; those in improvement of TCM symptoms were 40.18% (129/321) and 75. 23% (243/323) respectively, which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.
Key wordsSafflower yellow injection coronary heart disease angina pectoris Xin-Blood stagnation syndrome
Unable to display preview. Download preview PDF.
- 1.Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1st ed. Beijing: Chinese Publishing of Medical and Pharmaceutical Technique, 2002: 69–73.Google Scholar
- 2.Special Group of Clinical Nomenclature Standardization, International Association of Heart Diseases and WHO. Standard for nomenclature and diagnosis of ischemic heart disease. Chin J Cardiol 1981; 9(1): 75–76.Google Scholar
- 3.National Administration of Drugs Supervising and Managing. Technologic requirement for research of Chinese new drugs. 2000: 29–30.Google Scholar
- 4.Zheng QS, Sun RY, Chen ZY. Safety analysis on the regulation of minimal cases in clinical trial of new drugs. Chin J Clin Pharmacol Ther 2003; 8 (3): 354–355.Google Scholar
- 5.Zheng QS, Sun RY, Chen ZY. Discussion on the concise calculation and equivalent standard for sample assessment in new drug clinical trial. Chin New Drug J 2003;12 (5): 368–371.Google Scholar